, /PRNewswire/ -- The global liquid biopsy market size is estimated to grow by from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 25.2% during the forecast period.
Liquid biopsy techniques offer significant advantages over traditional biopsy methods in terms of accuracy and patient outcomes. Unlike traditional biopsies that often require invasive procedures, liquid biopsies use minimally invasive methods such as blood draws to detect circulating tumor DNA, RNA, or proteins shed by tumors into the bloodstream. This approach allows for earlier detection of cancer recurrence, monitoring treatment response, and identifying genetic mutations.
Despite challenges such as limited reimbursement, the market for liquid biopsy is propelled by increasing cancer incidence and substantial investments in technology and research by key players like A. Menarini, Guardant Health, and Roche. Get a detailed analysis on regions, market segments, customer landscape, and companies- Liquid biopsy has gained significant attention in recent years as a valuable research tool and advanced diagnostics technology.
This trend has attracted investors to fund the research and development of new liquid biopsy technologies and the production and commercialization of related products. Notable companies, including GRAIL, Guardant Health, Exosome Diagnostics, Pathway Genomics, and Inivata, have secured funding from various investors. For instance, Dxcover raised in Series A.
